In the last two decades, the number of pregnant women struggling with opioid use disorder (Oud) has increased in the US, increasing from just 1.5 per 1,000 tradition in 1999 to 8.2 to 2017.
A new study published in Jama Health Forum in April 2025 It shines new light on how critical the treatment is. The researchers found that pregnant people with und who received buprenorphine – a medication used to treat opioid addiction – had significantly better results than those who did not. The study, which attended more than 14,000 pairs of parent gasoline in Tennessee for a period of 11 years, offers strong evidence that expansion of access to buprenorfine could save lives and improve health effects across the boat.
Buprenorphine is a drug approved for the treatment of opioid addiction. Unlike methadone, which has been the golden model for decades, buprenorphine is considered safer in many ways. It works in part by activating opioid receptors in the brain – enough to facilitate withdrawal and cravings, but not enough to produce high. This “partial fighter” effect means that it has a lower risk of overdose, making the preferred choice during pregnancy.
The big question: Does it help in pregnancy?
The study started answering a critical question: the treatment of oud with buprenorfine during pregnancy leads to better results for both the mother and the baby?
The short answer is yes.
Researchers analyzed data from Tennessee’s Medicaid program, covering births from 2010 to 2021. From 14,463 pairs of maternal bombers where the pregnant person had oud, just more than half (51.6%) received buprenorphine treatment. The other half did not take any medicine for their addiction during pregnancy.
The results were impressive.
Basic findings: Buprenorphine saves lives and improves health
1. Fewer premature births
One of the clearer benefits of buprenorphine treatment was a significant decline in premature births – falsehoods born before 37 weeks pregnancy.
- Without treatment: 20% of infants were born prematurely.
- With buprenorphine: Only 14.1% were premature.
This is a 30% reduction in probability prematurely. In customized analyzes, the chances were further reduced, with a predicted probability of premature birth to just 11.7% in the treatment group.
2. Lower risk of mother’s serious morbidity (SMM)
Pregnancy is already a naturally demanding process, but for those who have OUD, the risks rise. The study found that women who received buprenorphine were significantly less likely to experience serious complications such as bleeding, heart problems or infection.
- Without treatment: 6.9% experienced SMM.
- With buprenorphine: only 5.4% experienced SMM.
This is a significant improvement, especially when it is considered that serious maternal complications are often a precursor to maternal death.
3. Reduced imports Nicu
Babies born to mothers with unprocessed Oud were also more likely to end up in the Intensive Neonatal Intensive Care Unit (NICU).
- Nicu imports: 17.2% without treatment versus 15.2% with treatment.
While this may seem like a small difference, it adds, especially when you think the Nicu stem is introduced to families and the healthcare system.
4. Overall, fewer negative results
When we look at the big picture – whether it is SMM, Nicu remains, premature birth or death of infants – the researchers found that only 20 people should be treated with buprenorphine to prevent a negative effect. This is a remarkably low number in terms of public health.
What about the disadvantages?
A point that can be seen about the increased percentage of neonatal opioid withdrawal syndrome in babies whose mothers were treated with buprenorphine, 51.7% compared to 32.4% in the group who was not treated.
But here is the shade: now it happens because the baby is exposed to opioid to the utero – even if it is a medical management dose. While withdrawal symptoms may require treatment, these babies are more likely to be complete, better nutritious and more resistant to babies born to mothers with unprocessed Oud, who may also be exposed to opioid road and have no prenatal care.
In short, the upds is therapeutic. The most serious results such as premature life, mother’s bleeding and ICU introduction have a much longer -term risk.
The study also emphasized a worrying trend: important racial inequalities in treatment.
- Only 2.1% of the people were black, compared to 10.2% of the group who was not treated.
- A separate US government report reported in the study found that only 18% of black women with Oud received treatment during pregnancy, compared to 48% of white women.
This suggests that black mothers are not only at a higher risk of bad results – they are also less likely to get the treatment that could help. Bridging this gap should be a priority for promoting its own health capital.
Obstacles to treatment: Why do the most pregnant people receive help?
Despite the clear benefits, many pregnant women still face obstacles to access to buprenorphine. These include:
- Foolish Provider: Some healthcare providers are reluctant to face pregnant people with Oud due to legal fears or lack of training.
- Insurance issues: Even with Medicaid, access to addictive experts or obgyns prescribing buprenorphine may be limited.
- Stigma: Pregnant people with substance use disorders often face a crisis, which can prevent them from searching for care.
- Legal consequences: In some states, substance use during pregnancy can lead to child care or even criminal charges.
These challenges make it even more urgent to shift public perception and policy to support treatment – not punishment.
The findings of this study are more than numbers. They represent real families, real pregnancies and real lives that are preserved or lost on the basis of access to care.
Using buprenorphine to treat oud during pregnancy:
- Mothers are less likely to face life -threatening complications.
- Babies are more likely to be born healthy and full.
- Families are more likely to thrive, not only to survive.
And because the study was done with a large population of real world for a decade, the results are incredibly relevant to public health programs and policies.
What should change?
To translate these findings into better results in all US, families need:
- More providers certified to prescribe buprenorphine – especially those who are trained to work with pregnant people.
- The reform of the policy of abolishing legal and insurance barriers that prevent people from seeking treatment.
- Viewing and training to reduce stigma around Oud during pregnancy.
- Initiatives focused on shares to ensure that people of all racial and ethnic backgrounds take care.
Overall, the study provides evidence that buprenorphine treatment during pregnancy is associated with better results for both mother and infant compared to no treatment. These include lower rates of premature birth, severe maternal morbidity and Nicu imports. While neonatal withdrawal was more common in the treatment group, other serious complications were less common.
More new pregnancy:
Pregnancy Package
This post includes subsidiaries where we will receive a small percentage if you buy through the link.
